Hemostemix Oversubscribed, Closing $2,700,000 Private Placement and Settles $400,000 of Debt at $0.20 per Share Read More
Hemostemix Announces the Appointment of Dr. Nadia Giannetti, MD, to its Scientific Advisory Board Read More
Hemostemix Submits its Retrospective Heart Study to Leading Stem Cell Journal and has Prepared its CLI Phase II Clinical Trial Manuscript for Peer Review Read More
